Search

Search results

[Translate to English:]

The EU-funded AiChemist project aims to provide advanced AI approaches with increased explainability and broad applicability. It brings together key players from academia and industry and includes a structured training program for AI specialists.

[Translate to English:]

The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.

The HIOH pursues an integrative approach to understanding the emergence of new pathogens and developing suitable intervention mechanisms. Ascenion is its technology transfer partner.

 

[Translate to English:]

Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.

[Translate to English:]

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

[Translate to English:]

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

[Translate to English:]

Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.

[Translate to English:]
  • T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
  • Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF
[Translate to English:]

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

Lead liver disease candidate to enter clinical trials this year

A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.

Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…